MIXTURES OF HMOs
    15.
    发明申请
    MIXTURES OF HMOs 审中-公开

    公开(公告)号:US20190290667A1

    公开(公告)日:2019-09-26

    申请号:US16435949

    申请日:2019-06-10

    Applicant: Glycom A/S

    Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2′-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2′-FL, and a component D, which is lactose when component A is 3-FL, or 2′-FL when component A is DFL, with the proviso that if component B is 2′-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.

    MIXTURES OF HUMAN MILK OLIGOSACCHARIDES COMPRISING 3 '-O-SIALYLLACTOSE

    公开(公告)号:US20180078574A1

    公开(公告)日:2018-03-22

    申请号:US15561684

    申请日:2016-03-31

    Applicant: Glycom A/S

    Abstract: A mixture of human milk oligosaccharides that consists essentially of 3′-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-O-fucosyl-3′-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3′-O-sialyllactose and component A with an α2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.

    MIXTURE OF HMOs
    18.
    发明申请

    公开(公告)号:US20230000127A1

    公开(公告)日:2023-01-05

    申请号:US17929905

    申请日:2022-09-06

    Applicant: GLYCOM A/S

    Abstract: A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto -N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or pre-venting viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

Patent Agency Ranking